THERAPEUTIC AREAS

Avir’s primary areas of therapeutic focus are the following:

Oncology / Supportive Care

GASTROENTEROLOGY

HOSPITAL ACUTE CARE

SURGICAL

WOMEN'S HEALTH

We are also always interested in new opportunities within other therapeutic areas if they meet the following criteria:

  • Has supporting clinical evidence
  • Is commercialization ready or in late stages of development (Phase III)
  • Responds to a well defined unmet need
  • Has strong intellectual property (IP)
  • Has an established competitive difference

AVIR’S PIPELINE STRATEGY

Acquire or in-license products for the Canadian market from the following 3 stages:

LAUNCH READY

  • Approved products (Rx, OTC & Medical Devices) that are commercial stage ready

  • Mature brands already commercialized in Canada

REGISTRATION READY

  • Medicines already commercialized in other countries and have a regulatory dossier (EU or FDA)

IN DEVELOPMENT PIII

  • Medicines that are in Phase III of development

  • Collaborations on additional clinical studies for Canadian registration and regulatory filing

PIPELINE

  • HOSPITAL – EMERGENCY CARE (2 PRODUCTS)

    Q1 2017 – Commercialized

  • GASTROENTEROLOGY (3 PRODUCTS)

    2018 – Launch

  • HOSPITAL (3 PRODUCTS)

    Q3 2018 – Launch

  • ONCOLOGY SUPPORTIVE CARE

    Q3 2018 – Launch

  • DERMATOLOGY

    2019 – Launch

  • WOMEN’S HEALTH

    2021 – Launch